VP 16-213 (VP 16) and cyclophosphamide in the treatment of primitive lung cancer in phase M I

Publisher Website
Google Scholar
Abstract
Sixty patients suffering from primitive lung cancer in Phase M I were included in two successive chemotherapy Protocols, 30 patients to a group. The first of these (an attempt at cellular synchronization by combining VCR-Cyclophosphamide-Prednisone) is used as a historical group as compared to the second. In the second protocol the combination of VP 16.213 (100 mg/m2, ev, day × 5 days) and cyclophosphamide (100 mg/m2, ev, day × 5 days) was attempted. The positive results obtained (more than 60% of the responses were above 50%) together with low toxicity was not accompanied by improvement of survival with respect to that observed in international medical literature. On the other hand, the number of cases studied-30 patients—was too low to permit a better evaluation of our results. Despite this fact, it seems appropriate to continue clinical investigation of the VP 16.213-Cyclophosphamide combination in lung cancer.